Abstract
Fifty years ago, the Eker rat was identified as the first animal model of hereditary renal adenoma and carcinoma [1], with histopathology resembling human renal carcinoma [2]. Ten years ago, a mutation in the TSC2 gene was identified in the Eker rat at Fox Chase Cancer Center by Yeung and Knudson [3], and in Tokyo by Kobayashi and Hino [4]. The literature contains dozens of reports of renal cell carcinoma (RCC) in tuberous sclerosis complex (TSC) patients, including tumors in children as young as five and one report in an infant. Despite these facts, the association between TSC and RCC is under-recognized, and sometimes completely omitted from discussions of inherited renal carcinoma. Here, we will review the clinical association of RCC in TSC, consider the factors that have led to its under-emphasis within the RCC field, address the cellular and biochemical mechanisms that may contribute to RCC in cells with TSC1 or TSC2 mutations, and finally discuss the ways in which the TSC signaling pathways may be linked to sporadic RCC in the general population.
Keywords: tuberous sclerosis complex, angiomyolipomas, renal cell carcinomas, polycystic kidney disease (pkd), birt-hogg-dube syndrome (bhd)
Current Molecular Medicine
Title: The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?
Volume: 4 Issue: 8
Author(s): Elizabeth Petri Henske
Affiliation:
Keywords: tuberous sclerosis complex, angiomyolipomas, renal cell carcinomas, polycystic kidney disease (pkd), birt-hogg-dube syndrome (bhd)
Abstract: Fifty years ago, the Eker rat was identified as the first animal model of hereditary renal adenoma and carcinoma [1], with histopathology resembling human renal carcinoma [2]. Ten years ago, a mutation in the TSC2 gene was identified in the Eker rat at Fox Chase Cancer Center by Yeung and Knudson [3], and in Tokyo by Kobayashi and Hino [4]. The literature contains dozens of reports of renal cell carcinoma (RCC) in tuberous sclerosis complex (TSC) patients, including tumors in children as young as five and one report in an infant. Despite these facts, the association between TSC and RCC is under-recognized, and sometimes completely omitted from discussions of inherited renal carcinoma. Here, we will review the clinical association of RCC in TSC, consider the factors that have led to its under-emphasis within the RCC field, address the cellular and biochemical mechanisms that may contribute to RCC in cells with TSC1 or TSC2 mutations, and finally discuss the ways in which the TSC signaling pathways may be linked to sporadic RCC in the general population.
Export Options
About this article
Cite this article as:
Henske Petri Elizabeth, The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359610
DOI https://dx.doi.org/10.2174/1566524043359610 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Chemistry and Biology of Curacin A
Current Pharmaceutical Design Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Current Drug Metabolism Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets The Use of Lentinan for Treating Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine